

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/589,288
Sheet	1	of	8	Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	
				PF343P3C5	

U.S. PATENT DOCUMENTS					
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication
		Application or Patent Number	Kind Code		
	XA	2002/0165156	A1	Browning et al.	11/07/2002
	XB	2002/0172674	A1	Browning et al.	11/21/2002
	XC	2003/0023038	A1	Rennert et al.	01/30/2003
	XD	2003/0194743	A1	Beltzer et al.	10/16/2003
	XE	2005/0214543	A1	Koumura et al.	09/29/2005
	XF	2005/0169924	A1	Browning et al.	08/04/2005
	XG	2006/0079457	A1	Browning et al.	04/13/2006
	XH	2007/0293434	A9	Beltzer et al.	12/20/2007
	XI	2008/0254030	A1	Mackay et al.	10/16/2008
	XJ	2008/0267965	A1	Kalled et al.	10/30/2008
	XK	2009/0081231	A1	Chevrier et al.	03/26/2009
	XL	2009/0098129	A1	Farrow et al.	04/16/2009
	XM	2009/0104189	A1	Yu et al.	04/23/2009
	XN	2009/0169565	A1	Yu et al.	07/02/2009
	XO	2009/0215071	A1	Cachero et al.	08/27/2009
	XP	2009/0110676	A1	Mackay et al.	04/30/2009
	XQ	2009/0221008	A1	Yu et al.	09/03/2009
	XR	2010/0003259	A1	Ruben et al.	01/07/2010
	XS	2010/0040627	A1	Browning et al.	02/18/2010
	XT	2010/0111953	A1	Ruben et al.	05/06/2010
	XU	2010/0144058	A1	Beltzer et al.	06/10/2010
	XV	5,589,499	A	Weth	12/31/1996
	XW	5,869,331	A	Dornburg	02/09/1999
	XX	5,948,619	A	Bandman et al.	09/07/1999
	XY	5,962,301	A	Horvitz et al.	10/04/1999
	XZ	6,207,160	B1	Victoria et al.	03/27/2001
	YA	7,083,785	B2	Browning et al.	08/01/2006
	YB	7,241,576	B2	Aggarwal	07/10/2007
	YC	7,691,804	B2	Browning et al.	04/06/2010

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Doc. No.	Foreign Patent Document		Name of Patentee or Applicant	Date of Publication	
		Office	Application or Patent Number	Kind Code	Translation *	
	YD	WO	99/46295	A1	Shanghai Second Medical University	09/16/1999
	YE	WO	99/47538	A1	Human Genome Sciences, Inc.	09/23/1999
	YF	WO	99/60127	A2	Genentech, Inc.	11/25/1999
	YG	EP	0 577 752	B1	Genentech, Inc.	07/05/2000
	YH	EP	0 910 635	B1	ZymoGenetics, Inc.	08/29/2007

Examiner Signature	Date Considered
--------------------	-----------------

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				<b>Complete if Known</b>
Application Number	09/589,288			
Filing Date	June 8, 2000			
First Named Inventor	Guo-Liang Yu			
Group Art Unit	1647			
Examiner Name	Bridget E. Bunner			
Attorney Docket Number	702041			

Sheet **2** of **8** Client Reference No. **PF343P3C5**

### OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	YI	DANIEL et al., <i>Virology</i> , "Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: A Combination of Nine Prediction Algorithms Fails To Identify Relevant Epitopes and Peptide Immunogenicity Is Drastically Influenced by the Nature of the Protein Carrier," 202:540-549 (1994)	
	YJ	FREIMUTH, "Lessons learned from the Phase 2 belimumab SLE study: development of an SLE responder index," June 1, 2009	
	YK	HARLOW and LANE eds., <i>Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Press, pp. 15 and 626-631 (1988)	
	YL	LEDERMAN et al., <i>Mol. Immunol.</i> , "A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4," 28(11):1171-1181 (1991)	
	YM	LI et al., <i>Proc. Natl. Acad. Sci. USA</i> , "β-Endorphin omission analogs:Dissociation of immunoreactivity from other biological activities," 77(6):3211-3214 (1980)	
	YN	NERI et al., <i>Clin. Cancer Res.</i> , "Neutralizing B-Cell – Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model," 13(19):5903-5909 (2007)	
	YO	SHIVAKUMAR et al., <i>Clin. Lymphoma Myeloma</i> , "Targeting B-Lymphocyte Stimulator/B-Cell Activating Factor and a Proliferation-Inducing Ligand in Hematologic Malignancies," 7(2):106-108 (2006)	
	YP	Final Rejection issued in U.S. Patent Application No. 11/232,439, dated May 27, 2009	
	YQ	Advisory Action issued in U.S. Patent Application No. 11/232,439, dated August 14, 2009	
	YR	Non-Final Rejection issued in U.S. Patent Application No. 11/232,439, dated November 5, 2009	
	YS	Requirement for Restriction/Election issued in U.S. Patent Application No. 12/170,333, dated May 28, 2009	
	YT	Non-Final Rejection issued in U.S. Patent Application No. 12/170,333, dated September 17, 2009	
	YU	Requirement for Restriction/Election issued in U.S. Patent Application No. 12/210,134, dated June 24, 2009	
	YV	Requirement for Restriction/Election issued in U.S. Patent Application No. 12/393,693, dated June 25, 2009	
	YW	International Preliminary Examination Report issued in PCT Patent Application No. PCT/US06/38756, dated May 29, 2009	
	YX	BENDIG, <i>Methods: A Comparison to Methods in Enzymology</i> , "Humanization of Rodent Monoclonal Antibodies by CDR Grafting," 8:83-93 (1995)	
	YY	Non-Final Rejection issued in U.S. Patent Application No. 12/210,134, dated November 30, 2009	
	YZ	COPE et al., <i>Curr. Opin. Immunol.</i> , "Emerging approaches for the therapy of autoimmune and chronic inflammatory disease," 16: 780-786 (2004)	
	ZA	Requirement for Restriction/Election issued in U.S. Patent Application No. 12/552,915, dated December 1, 2009	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/589,288
Sheet	3	of	8	Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
Z B		BETTER et al, "T Cell-targeted Immunofusion Proteins from Escherichia coli", <i>The Journal of Biological Chemistry</i> , 270(25): 14951-14957 (1995)	
Z C		Extended European Search Report, European Application No. 06851283.9 dated November 3, 2009	
Z D		American College of Rheumatology, "The 1982 Revised Criteria for Classification of Systemic Lupus Erythematosus," from URL: <a href="http://www.rheumatology.org/publications/classification/SLE/sle.asp">http://www.rheumatology.org/publications/classification/SLE/sle.asp</a>	
Z E		AGUIRRE-CRUZ et al., <i>J. Neurooncol.</i> , "Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases," 71(1):39-41 (2005)	
Z F		ERIKSSON et al., <i>Ann. Rheum. Dis.</i> , "Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFalpha," 64(3):403-407 (2005)	
Z G		KEYSTONE, <i>Arthritis Res. Ther.</i> , "B cell targeted therapies," 7(3):S13-S18 (2005)	
Z H		MYCKATYN et al., <i>J. Rheumatol.</i> , "Outcome of positive antinuclear antibodies in individuals without connective tissue disease," 30(4):736-739 (2003)	
Z I		Notification of decision of the Technical Board of Appeals in Appeal Case T 18/09-3.3.08 in EP Patent 0 939 804, dated December 1, 2009	
Z J		Notice of Allowance issued in U.S. Patent Application No. 11/054,515, dated December 21, 2009	
Z K		NICHOLS et al., <i>Eur. J. Cancer</i> , "Interleukin-2 Fusion Protein: An Investigational Therapy for Interleukin-2 Receptor Expressing Malignancies," 33(1):S34-S36 (1997)	
Z L		SWEENEY et al., <i>Bioconjug. Chem.</i> , "Interleukin 7 (IL-7) Receptor-Specific Cell Killing by DAB <sub>389</sub> IL-7: A Novel Agent for the Elimination of IL-7 Receptor Positive Cells," 9:201-207 (1998)	
Z M		ALCAMI et al., <i>J. Immunol.</i> , "Blockade of Chemokine Activity by a Soluble Chemokine Binding Protein from Vaccinia Virus," 160:624-633 (1998)	
Z N		FLEMING et al., <i>J. Mol. Recognit.</i> , "Discovery of High-Affinity Peptide Binders to BLyS by Phage Display," 18:94-102 (2005)	
Z O		SUN et al., <i>Biochem. Biophys. Res. Commun.</i> , "A Novel BLyS Antagonist Peptide Designed Based on the 3-D Complex Structure of BCMA and BLyS," 346:1158-1162 (2006)	
Z P		Requirement for Restriction/Election issued in U.S. Patent Application No. 12/135,025, dated March 9, 2010	
Z Q		Non-Final Rejection issued in U.S. Patent Application No. 12/552,915, dated April 8, 2010	
Z R		Requirement for Restriction/Election issued in U.S. Patent Application No. 12/605,202, dated April 8, 2010	
Z S		Requirement for Restriction/Election issued in U.S. Patent Application No. 12/701,301, dated May 3, 2010	
Z T		Final Rejection issued in U.S. Patent Application No. 12/170,333, dated May 28, 2010	
Z U		Final Rejection issued in U.S. Patent Application No. 12/393,693, dated May 28, 2010	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/589,288
Sheet	4	of	8	Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
ZV	HGS Press Release, "Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of Benlysta™ in Systemic Lupus Erythematosus" (April 20, 2010)		
ZW	Non-Final Rejection issued in U.S. Patent Application No. 12/186,404, dated June 21, 2010		
ZX	HGS Miscellaneous Motion 3 (to exclude RDF Exhibits 1010 and 1013-1016) filed in Patent Interference 105,652. Filed in the United States Patent Office on May 6, 2009.		
ZY	RDF Miscellaneous Motion 1 (Motion to Exclude Evidence) filed in Patent Interference 105,652. Filed in the United States Patent Office on May 6, 2009.		
ZZ	HGS Opposition 1A (Opposing RDF Miscellaneous Motion 1 to exclude evidence) filed in Patent Interference 105,652. Filed in the United States Patent Office on May 14, 2009.		
AAA	RDF Opposition to HGS Miscellaneous Motion 3 (Motion to Exclude) filed in Patent Interference 105,652. Filed in the United States Patent Office on May 14, 2009.		
AAB	HGS Reply 3 (to exclude RDF Exhibits 1010 and 1013-1016) filed in Patent Interference 105,652. Filed in the United States Patent Office on May 21, 2009.		
AAC	HGS Exhibit List (as of May 28, 2009) filed in Patent Interference 105,652. Filed in the United States Patent Office on May 28, 2009.		
AAD	HGS Demonstratives from Oral Hearing, dated July 2, 2009. Filed in Patent Interference 105,652.		
AAE	Transcript of Oral Hearing, dated September 4, 2009. Filed in Patent Interference 105,652.		
AAF	AGGARWAL et al., <i>Eur. Cytokine Netw.</i> , 7(2): 93-124 (1996)		
AAG	ARAI et al., <i>Annu. Rev. Biochem.</i> , 59: 783-836 (1990)		
AAH	BAUMANN et al., <i>J. Biol. Chem.</i> , 268(12): 8414-8417 (1993)		
AAI	COLLINS et al., <i>Proc. Natl. Acad. Sci. USA</i> , 83: 446-450 (1986)		
AAJ	FUJIO et al., <i>Blood</i> , 95(7): 2204-2211 (2000)		
AAK	GEARING et al., <i>Embo. J.</i> , 10(10): 2839-2848 (1991)		
AAL	GINALDI et al., <i>J. Clin. Pathol.</i> , 51: 364-369 (1998)		
AAM	HOLMES et al., <i>Science</i> , 253: 1278-1280 (1991)		
AAN	HUNTINGTON et al., <i>Int. Immunol.</i> , 18(10): 1473-1485 (2006)		
AAO	JANEWAY et al., <i>Immunobiology: The Immune System in Health and Disease</i> , Current Biology Ltd./Garland Publishing, London. pp. 2:31, 7:1-7:41 (1996)		
AAP	KAWAGUCHI et al., <i>J. Allergy Clin. Immunol.</i> , 114(6): 1265-1273 (2004)		
AAQ	LASAGNI et al., <i>Blood</i> , 109(10): 4127-4134 (2007)		
AAR	LAVIE et al., <i>J. Pathol.</i> , 202: 496-502 (2004)		
AAS	LAWN et al., <i>Cell</i> , 15: 1157-1174 (1978)		
AAT	MANIATIS et al., <i>Cell</i> , 15: 687-701 (1978)		
AAU	MIYAJIMA et al., <i>Annu. Rev. Immunol.</i> , 10: 295-331 (1992)		
AAV	PABST et al., <i>Anat. Embryol.</i> , 192: 293-299 (1995)		
AAW	RANGES et al., <i>J. Exp. Med.</i> , 167: 1472-1478 (1988)		
AAX	ROCHMAN et al. <i>J. Immunol.</i> , 178: 6720-6724 (2007)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	5	of	8	Client Reference No.	PF343P3C5
-------	---	----	---	----------------------	-----------

### Complete if Known

Application Number	09/589,288
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Group Art Unit	1647
Examiner Name	Bridget E. Bunner
Attorney Docket Number	702041

### OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
AAY		SHAN et al., <i>Physiol. Res.</i> , 55: 301-307 (2006)	
AAZ		SIEGEL et al., <i>Nat. Immunol.</i> , 1(6): 469-474 (2000)	
BBA		STEIN et al., <i>J. Clin. Invest.</i> , 109: 1587-1598 (2002)	
BBB		STOECKLE et al., <i>New Biol.</i> , 2(4): 313-323 (1990)	
BBC		WANG et al., <i>Nat. Immunol.</i> , 2(7): 632-637 (2001)	
BBD		WATERSTON et al., <i>Nat. Genet.</i> , 1: 114-123 (1992)	
BBE		XU et al., <i>Acta Biochim. Biophys. Sin.</i> , 39(12): 964-973 (2007)	
BBF		XU et al., <i>Transplant. Proc.</i> , 41: 1552-1556 (2009)	
BBG		YOKOTA et al., <i>J. Immunol.</i> , 140(2): 531-536 (1988)	
BBH		YOSHIMOTO et al., <i>Int. Immunol.</i> , 18(7): 1189-1196 (2006)	
BBI		Eli Lilly letter on Statement on Grounds of Appeal filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on May 1, 2009)	
BBJ		HGS Press Release, "Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for Benlysta™" (July 20, 2009)	
BBK		Declaration of Amy Hamilton filed in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 23, 2009)	
BBL		Eli Lilly letter to Technical Board of Appeals regarding Response to Appeal in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 23, 2009)	
BBM		Eli Lilly Response to Appeal filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 23, 2009)	
BBN		Declaration and Curriculum Vitae of Dr. Thomas Lane Rothstein filed in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 27, 2009)	
BBO		Second Declaration of Dr. John Calley filed in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 27, 2009)	
BBP		Signed Declaration of Dr. Thomas Lane Rothstein filed in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 27, 2009)	
BBQ		HGS letter on Grounds of Appeal update filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on July 31, 2009)	
BBR		Preliminary Opinion of the Board of Appeal in Appeal Case T 18/09-3.3.08 in EP Patent 0939804 (August 24, 2009)	
BBS		Auxiliary Request I filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)	
BBT		Auxiliary Request II filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)	
BBU		Auxiliary Request III filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)	
BBV		Auxiliary Request IV filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)	
BBW		Auxiliary Request V filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)	

Examiner Signature

Date Considered

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/589,288
Sheet	6	of	8	Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5

**OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
BBX	Eli Lilly Reply to Preliminary Opinion filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
BBY	Further Declaration of Dr. John Calley filed in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
BBZ	HGS Reply to Preliminary Opinion filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCA	Main Request filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCB	Second Declaration of Dr. Garnett Herrel Kelsoe III and list of annexes filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCC	Second Declaration of Dr. Randolph J. Noelle filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCD	Second Declaration of Dr. Stuart Farrow filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCE	Summary of Respondent's Proposed Experiments filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCF	Third Declaration of Dr. Andrew Martin and Appendix 1 filed before Technical Board of Appeals in Opposition of EP Patent No. 0 939 804 (Filed in the European Patent Office on September 30, 2009)		
CCG	Minutes of the Oral Proceedings before the Opposition Division, issued by the European Patent Office in the matter of Eli Lilly's Opposition of EP 0 939 804 (October 26, 2009)		
CCH	Eli Lilly's Skeleton Argument on appeal in UK Revocation suit HC06CO2687 (October 30, 2009)		
CCI	Human Genome Science's Consolidated Skeleton Argument on appeal in UK Revocation suit HC06CO2687 (December 2009)		
CCJ	Eli Lilly's Note on the Decision of the TBA in T18/09 in UK Revocation suit HC06CO2687 (December 4, 2009)		
CCK	Eli Lilly's Note on why the Decision of the TBA in T18/09 is different on the Facts in UK Revocation suit HC06CO2687 (December 11, 2009)		
CCL	Human Genome Science's mark-up of Eli Lilly's Note on why the Decision of the TBA in T18/09 is different on the Facts in UK Revocation suit HC06CO2687 (December 11, 2009)		
CCM	Human Genome Science's Note on why the Invention is susceptible of Industrial Application in UK Revocation suit HC06CO2687 (December 10, 2009)		
CCN	Human Genome Science's Note on paragraph 26 of Judgment by Mr Justice Kitchin in UK Revocation suit HC06CO2687 (December 2009)		
CCO	Human Genome Science's Reply Note in UK Revocation suit HC06CO2687 (December 11, 2009)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	09/589,288
Sheet	7	of	8	Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
				Client Reference No.	PF343P3C5

#### OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	CCP	Approved Judgment by Mr Justice Jacob on appeal from the Chancery Division in UK Revocation suit HC06CO2687 (February 9, 2010)	
	CCQ	Notification of decision of the Technical Board of Appeals in Appeal Case T 18/09-3.3.08 in EP Patent 0 939 804 (October 21, 2009)	
	CCR	Memorandum opinion and order issued June 29, 2010 in Patent Interference No. 105,652	
	CCS	Judgment on preliminary motions issued June 29, 2010 in Patent Interference No. 105,652	
	CCT	"Classification Criteria for the Diagnosis of Systemic Lupus Erythematosus," retrieved July 22, 2010 from <a href="http://medicalcriteria.com/criteria/sle.htm">http://medicalcriteria.com/criteria/sle.htm</a>	
	CCU	Final Rejection issued in U.S. Patent Application No. 12/210,134, dated July 21, 2010	
	CCV	EL-HALLAK et al., <i>J. Pediatr.</i> , "Clinical Effects and Safety of Rituximab for Treatment of Refractory Pediatric Autoimmune Diseases," 150:376-382 (2007)	
	CCW	TAN et al., <i>Arthritis Rheum.</i> , "Range of antinuclear antibodies in "healthy" individuals," 40(9):1601-1611 (1997)	
	CCX	PETRI et al., <i>N. Engl. J. Med.</i> , "Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus," 353(24):2550-2558 (2005)	
	CCY	SAUGE-MERLE et al., <i>Eur. J. Biochem.</i> , "An active ribonucleotide reductase from <i>Arabidopsis thaliana</i> : cloning, expression and characterization of the large subunit," 266:62-69 (1999)	
	CCZ	ESPOSITO et al., <i>J. Immunol.</i> , "Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients," 163:4027-4032 (1999)	
	DDA	International Search Report issued in PCT Application No. PCT/US01/25850, dated April 1, 2003	
	ddb	International Search Report issued in PCT Application No. PCT/US01/25891, dated April 2, 2003	
	DDC	Requirement for Restriction/Election issued in U.S. Patent Application No. 09/932,322, dated June 30, 2004	
	DDD	Non-Final Rejection issued in U.S. Patent Application No. 09/932,322, dated February 9, 2005	
	DDE	Final Rejection issued in U.S. Patent Application No. 09/932,322, dated August 24, 2005	
	DDF	Notice of Allowance issued in U.S. Patent Application No. 09/932,322, dated February 8, 2006	
	DDG	HAN et al., "Characterization of Transformation Function of Cottontail Rabbit Papillomavirus E5 and E8 Genes," <i>Virology</i> , 251:253-263 (1998)	
	DDH	Non-Final Rejection issued in U.S. Patent Application No. 12/135,025, dated August 4, 2010	
	DDI	Notice of Allowance issued in U.S. Patent Application No. 11/054,515, dated September 9, 2010	
	DDJ	Non-Final Rejection issued in U.S. Patent Application No. 12/605,202, dated September 20, 2010	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

Please type a plus sign (+) inside this box → +

+

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	09/589,288
				Filing Date	June 8, 2000
				First Named Inventor	Guo-Liang Yu
				Group Art Unit	1647
				Examiner Name	Bridget E. Bunner
				Attorney Docket Number	702041
Sheet	8	of	8	Client Reference No.	PF343P3C5

#### **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Signature \_\_\_\_\_ Date Considered \_\_\_\_\_

\* If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.